Cerecin (formerly known as CereSpir) is a clinical-stage pharmaceutical company developing novel therapeutics for Alzheimer's disease and other central nervous system disorders. The company's lead compound, AZD-0328, targets the cholinergic system to improve cognitive function.
Overview
flowchart TD
companies_cerecin["Cerecin"]
style companies_cerecin fill:#4fc3f7,stroke:#333,color:#000
companies_cerecin_0["Funding"]
companies_cerecin -->|"includes"| companies_cerecin_0
style companies_cerecin_0 fill:#81c784,stroke:#333,color:#000
companies_cerecin_1["History and Background"]
companies_cerecin -->|"includes"| companies_cerecin_1
style companies_cerecin_1 fill:#ef5350,stroke:#333,color:#000
companies_cerecin_2["Pipeline and Programs"]
companies_cerecin -->|"includes"| companies_cerecin_2
style companies_cerecin_2 fill:#ffd54f,stroke:#333,color:#000
companies_cerecin_3["AZD-0328 formerly CSP-033"]
companies_cerecin -->|"includes"| companies_cerecin_3
style companies_cerecin_3 fill:#ce93d8,stroke:#333,color:#000
companies_cerecin_4["Additional Programs"]
companies_cerecin -->|"includes"| companies_cerecin_4
style companies_cerecin_4 fill:#4fc3f7,stroke:#333,color:#000
companies_cerecin_5["Scientific Approach"]
companies_cerecin -->|"includes"| companies_cerecin_5
style companies_cerecin_5 fill:#81c784,stroke:#333,color:#000
...Cerecin (formerly known as CereSpir) is a clinical-stage pharmaceutical company developing novel therapeutics for Alzheimer's disease and other central nervous system disorders. The company's lead compound, AZD-0328, targets the cholinergic system to improve cognitive function.
Overview
Mermaid diagram (expand to render)
- Founded: 2014
- Headquarters: Cambridge, Massachusetts, USA (originally Sydney, Australia)
- Focus: Alzheimer's disease and cognitive disorders
- Stage: Clinical stage
- Formerly: CereSpir, spinout from University of Sydney
- Website: [https://www.cerecin.com/](https://www.cerecin.com/)
Funding
- Type: Private
- investor: Based on Cambridge biotech ecosystem
History and Background
Cerecin was founded in 2014 as a spinout from the University of Sydney, initially operating under the name CereSpir. The company was established to commercialize research from the university's Brain and Mind Centre, which had been conducting pioneering work on cholinergic signaling and nicotinic acetylcholine receptors.
In 2019, Cerecin relocated its headquarters from Sydney, Australia to Cambridge, Massachusetts, aligning with the company's strategic goal of accessing the deeper biotech ecosystem and investor base in the United States. This move positioned Cerecin among the world's leading biotechnology clusters and facilitated stronger partnerships with major pharmaceutical companies[@cerecin2026].
The company's name change from CereSpir to Cerecin reflected its evolution from a research-focused startup to a clinically-oriented biopharmaceutical company with broader ambitions in CNS drug development.
Pipeline and Programs
Cerecin's lead compound is a novel positive allosteric modulator (PAM) of the alpha-7 nicotinic [acetylcholine](/entities/acetylcholine) receptor (α7 nAChR). This receptor plays a critical role in cognitive function, attention, and memory, and is a validated target for Alzheimer's disease therapeutics[@cerecin2026].
- Indication: Alzheimer's disease
- Mechanism: Alpha-7 nicotinic acetylcholine receptor positive allosteric modulator
- Target: α7 nAChR in [hippocampus](/brain-regions/hippocampus) and cortical regions
- Status: Clinical development
- History: Previously showed safety and efficacy signals in Phase 1b/2a trials
Clinical Development History
AZD-0328 has undergone extensive preclinical and clinical evaluation:
Preclinical studies: Demonstrated robust cognitive enhancement in multiple animal models including aged rodents and non-human primates
Phase 1 trials: Established safety and tolerability in healthy volunteers
Phase 1b/2a trials: Showed preliminary efficacy signals in patients with Alzheimer's diseaseAdditional Programs
Cerecin continues to explore additional compounds targeting neurodegenerative diseases through modulation of nicotinic acetylcholine receptors and other cognitive pathways[@cerecin2026a]. The company's pipeline includes:
- Novel nicotinic receptor modulators: Next-generation compounds with improved pharmacological profiles
- Combination therapy approaches: Investigating synergistic combinations with existing AD treatments
- Indications beyond Alzheimer's: Exploring applications in other cognitive disorders
Scientific Approach
Alpha-7 Nicotinic Receptor Modulation
The alpha-7 nicotinic acetylcholine receptor is a ligand-gated ion channel abundant in brain regions involved in cognition, including the hippocampus and prefrontal [cortex](/brain-regions/cortex). In Alzheimer's disease, α7 nAChR function is often impaired, contributing to cognitive deficits[@alpha2026].
Benefits of positive allosteric modulation:
Preserves normal receptor signaling: PAMs enhance normal neurotransmission without directly activating receptors, maintaining physiological signaling
Improved safety profile: Allosteric modulators typically have fewer side effects than direct agonists
Broader therapeutic window: Allows for more nuanced dosing and reduced risk of receptor desensitizationCholinergic System in dementia
The cholinergic system plays a crucial role in memory and attention. In Alzheimer's disease, there is progressive loss of cholinergic [neurons](/entities/neurons) in the basal forebrain, leading to decreased acetylcholine levels in key brain regions. This cholinergic deficit is a hallmark of AD and underlies many of the cognitive symptoms experienced by patients.
Cerecin's approach targets this deficit directly by enhancing signaling through the α7 nAChR, which may help compensate for lost cholinergic input and improve cognitive function in AD patients.
Business Development and Partnerships
Cerecin has established several strategic partnerships to advance its pipeline:
- University collaborations: Ongoing research partnerships with leading academic institutions studying cholinergic signaling
- Contract research organizations: Partnerships with CROs for preclinical and clinical development activities
- Potential pharma partnerships: The company has sought partnerships with larger pharmaceutical companies for late-stage development and commercialization
Competitive Landscape
Cerecin operates in the competitive Alzheimer's disease therapeutic space, competing with:
- Large pharmaceutical companies: Including Biogen, Eli Lilly, and Roche in the AD therapeutics market
- Other biotech companies: Several biotechnology companies developing nicotinic receptor modulators and other cognitive enhancement approaches
- Generic [cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Currently approved AD treatments ([donepezil](/entities/donepezil), [rivastigmine](/entities/rivastigmine), galantamine) represent existing competition
Cerecin differentiates itself through its novel mechanism of action targeting α7 nAChR, which may offer advantages over existing cholinesterase inhibitors.
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Cholinergic System](/mechanisms/cholinergic-signaling)
- [Acetylcholine](/entities/acetylcholine)
- [Pharmaceutical Companies Index](/companies)
- [--](/proteins/n--cadherin-protein)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Unknown, Cerecin company history and background. Retrieved 2026-03-22 (2026)
Unknown, Cerecin pipeline and programs (2026)
Unknown, Alpha-7 nicotinic acetylcholine receptor in Alzheimer's disease (2026)
Unknown, ClinicalTrials.gov search for AZD-0328 (2026)Pathway Diagram
The following diagram shows the key molecular relationships involving Cerecin discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)